Obsidian Therapeutics (NASDAQ:OBX) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Obsidian Therapeutics (NASDAQ:OBX) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $39.00.

OBX has been the subject of a number of recent research reports. William Blair upgraded shares of Obsidian Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Piper Sandler started coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target for the company. Leerink Partners initiated coverage on Obsidian Therapeutics in a report on Tuesday, September 22nd. They issued an “outperform” rating and a $32.00 price target for the company. Wall Street Zen upgraded Obsidian Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, September 27th. Finally, Weiss Ratings initiated coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock.

Obsidian Therapeutics Stock Performance

Shares of NASDAQ:OBX opened at $12.24 on Friday. Obsidian Therapeutics has a 1 year low of $12.07 and a 1 year high of $49.97. The company’s 50 day simple moving average is $18.36.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.

The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.

Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information.